Skip to main content
Premium Trial:

Request an Annual Quote

Baebies Receives CE Mark for Molecular POC SARS-CoV-2 Test

NEW YORK – Molecular diagnostic firm Baebies announced on Thursday that its Finder SARS-CoV-2 point-of-care test has received CE marking.

The RT-PCR test runs on the company's compact Finder 1.5 instrument, which uses digital microfluidics technology to miniaturize the PCR process. The single-use assay qualitatively detects RNA from the virus in both nasopharyngeal and nasal swab samples, returning results in about 17 minutes, the Durham, North Carolina-based company said in a statement.

Baebies currently has other test panels under development for the Finder 1.5 platform using the same cartridge format, it added. The company previously received up to $11.6 million in funding from the global nonprofit Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator to develop the platform for sepsis testing for neonates and children. 

It has also received CE marking for two newborn screening assays and a glucose-6-phosphate dehydrogenase test.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.